DE602007010664D1 - P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen - Google Patents

P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen

Info

Publication number
DE602007010664D1
DE602007010664D1 DE602007010664T DE602007010664T DE602007010664D1 DE 602007010664 D1 DE602007010664 D1 DE 602007010664D1 DE 602007010664 T DE602007010664 T DE 602007010664T DE 602007010664 T DE602007010664 T DE 602007010664T DE 602007010664 D1 DE602007010664 D1 DE 602007010664D1
Authority
DE
Germany
Prior art keywords
benzoylthine
activating
oxygen compounds
benzoyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007010664T
Other languages
German (de)
English (en)
Inventor
Sonia Lain
David Phillip Lane
Michael John Raymond Stark
Anna Rose Mccarthy
Jonathan James Hollick
Nicholas James Westwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of St Andrews
University of Dundee
Original Assignee
University of St Andrews
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0617278A external-priority patent/GB0617278D0/en
Priority claimed from GB0625929A external-priority patent/GB0625929D0/en
Application filed by University of St Andrews, University of Dundee filed Critical University of St Andrews
Publication of DE602007010664D1 publication Critical patent/DE602007010664D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/24—Derivatives of thiourea containing any of the groups, X being a hetero atom, Y being any atom
    • C07C335/26—Y being a hydrogen or a carbon atom, e.g. benzoylthioureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602007010664T 2006-09-04 2007-09-04 P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen Active DE602007010664D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0617278A GB0617278D0 (en) 2006-09-04 2006-09-04 P53 activating compounds
GB0625929A GB0625929D0 (en) 2006-12-23 2006-12-23 P53 activating compounds
PCT/GB2007/003302 WO2008029096A2 (en) 2006-09-04 2007-09-04 P53 activating benzoyl urea and benzoyl thiourea compounds

Publications (1)

Publication Number Publication Date
DE602007010664D1 true DE602007010664D1 (de) 2010-12-30

Family

ID=38819391

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007010664T Active DE602007010664D1 (de) 2006-09-04 2007-09-04 P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen

Country Status (6)

Country Link
US (2) US8501991B2 (cg-RX-API-DMAC7.html)
EP (1) EP2099445B1 (cg-RX-API-DMAC7.html)
JP (1) JP5506386B2 (cg-RX-API-DMAC7.html)
AT (1) ATE488232T1 (cg-RX-API-DMAC7.html)
DE (1) DE602007010664D1 (cg-RX-API-DMAC7.html)
WO (1) WO2008029096A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US8580488B2 (en) * 2007-02-05 2013-11-12 City Of Hope Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance
US8952028B2 (en) 2007-02-05 2015-02-10 City Of Hope Methods of treating chemoresistance and relapse in cancer cells
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US20100137345A1 (en) * 2007-05-14 2010-06-03 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
WO2011022028A2 (en) * 2009-05-18 2011-02-24 Tufts University Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof
GB0909912D0 (en) 2009-06-09 2009-07-22 Univ Dundee Compounds
WO2011103375A1 (en) 2010-02-19 2011-08-25 Siga Technologies, Inc. Inhibitors and methods of inhibiting bacterial and viral pathogens
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
US10016414B2 (en) 2010-11-12 2018-07-10 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
FR2980477B1 (fr) * 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
JP6450191B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR20160006215A (ko) * 2013-05-13 2016-01-18 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 가교 우레아 유사체
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016049355A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
CN115724780B (zh) * 2022-11-17 2024-04-26 武汉大学 一种基于疏水标签的酰基硫脲类化合物及其制备方法与抗甲型流感病毒的应用
CN117069631A (zh) * 2023-08-15 2023-11-17 北京中医药大学 一种具有抗肿瘤活性的新型硫脲类化合物及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0116728B1 (en) * 1983-01-24 1987-08-12 Duphar International Research B.V Composition active against mites, whitefly and thrips, pharmaceutical composition, and new benzoylureau compounds
EP0117320B1 (en) * 1983-01-24 1987-03-04 Duphar International Research B.V Benzoylurea compounds, and pesticidal compositions comprising same
ATE43788T1 (de) * 1983-09-01 1989-06-15 Duphar Int Res Benzoylharnstoffe mit antitumoraler wirkung.
DK88186A (da) * 1985-03-01 1986-09-02 Duphar Int Res Benzoylurinstofderivater med antitumoraktivitet
AU642524B2 (en) 1990-09-10 1993-10-21 Duphar International Research B.V. Pharmaceutical formulation containing a benzoyl urea derivative
JPH05247001A (ja) * 1991-12-05 1993-09-24 Ishihara Sangyo Kaisha Ltd 置換ベンゾイルウレア誘導体又はその塩、それらの製造方法及びそれらを含有する抗癌剤
KR950026862A (ko) * 1994-03-15 1995-10-16 강박광 벤조일 우레아 유도체
JPH07285952A (ja) * 1994-04-08 1995-10-31 Fujisawa Pharmaceut Co Ltd 新規複素環誘導体
US20060004085A1 (en) * 2002-03-29 2006-01-05 University Of Maryland , Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
WO2004014885A1 (en) 2002-08-07 2004-02-19 Neuraxon Inc. Amino benzothiazole compounds with nos inhibitory activity
US7087761B2 (en) * 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
EP1874952A2 (en) 2005-04-11 2008-01-09 Achillion Pharmaceuticals, Inc. Pharmaceutical compositions for and methods of inhibiting hcv replication

Also Published As

Publication number Publication date
US8501991B2 (en) 2013-08-06
JP5506386B2 (ja) 2014-05-28
US20110021529A1 (en) 2011-01-27
WO2008029096A2 (en) 2008-03-13
ATE488232T1 (de) 2010-12-15
US20130310382A1 (en) 2013-11-21
US9120765B2 (en) 2015-09-01
JP2010502582A (ja) 2010-01-28
WO2008029096A3 (en) 2008-04-24
EP2099445A2 (en) 2009-09-16
EP2099445B1 (en) 2010-11-17
WO2008029096A8 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EA201170521A1 (ru) Новые соединения
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2007115821A3 (en) Organic compounds
EA201171367A1 (ru) Винилиндазолильные соединения
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MY153915A (en) Organic compounds
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
TNSN08400A1 (en) Organic compounds and their uses
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
AU2007249926A8 (en) Monocyclic heteroaryl compounds
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
EA200970472A1 (ru) Замещенные пиразолы, композиции, их содержащие, способ получения и применение